GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Gossamer Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$8.43−0.34 (-3.88%)
Close on Oct 19, 2026
- Market cap
- $2.77B
- P/E (TTM)
- –
- Dividend yield
- –
Gossamer Bio statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Gossamer Bio | Industry median |
|---|---|---|
| Market Cap | $4.12B | $197.05M |
| Enterprise Value | $4.06B | $106.56M |
| PS Ratio | 77.34 | 3.93 |
Enterprise value
| Measure | Gossamer Bio | Industry median |
|---|---|---|
| EV / Sales | 76.27 | 2.69 |
Income (trailing twelve months)
| Measure | Gossamer Bio | Industry median |
|---|---|---|
| Revenue | $53.29M | $57.94M |
| Operating Income | -$166.09M | -$21.44M |
| Net Income | -$125.22M | -$22.46M |
| EBITDA | -$166.09M | -$16.91M |
| EPS (Diluted) | -$0.69 | -$0.83 |
Margins
| Measure | Gossamer Bio | Industry median |
|---|---|---|
| Operating Margin | -311.7% | -44.5% |
| Profit Margin | -235.0% | -39.2% |
| EBITDA Margin | -311.7% | -31.3% |
| FCF Margin | -305.2% | -8.85% |
Returns
| Measure | Gossamer Bio | Industry median |
|---|---|---|
| Return on Assets (ROA) | -78.8% | -41.0% |
Growth
| Measure | Gossamer Bio | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 32.4% | 6.01% |
Balance sheet
| Measure | Gossamer Bio | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $57.03M | $62.42M |
| Net Cash (Debt) | $57.03M | $15.68M |
| Net Cash Per Share | $0.12 | $0.65 |
| Equity (Book Value) | -$94.03M | $48.79M |
| Book Value Per Share | -$0.19 | $1.36 |
| Tangible Book Value | -$94.03M | $23.06M |
| Working Capital | -$65.06M | $75.77M |
Financial position
| Measure | Gossamer Bio | Industry median |
|---|---|---|
| Current Ratio | 0.53 | 3.30 |
| Quick Ratio | 0.46 | 2.39 |
| Interest Coverage | -15.16 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Gossamer Bio | Industry median |
|---|---|---|
| Operating Cash Flow | -$162.63M | -$12.35M |
| Capital Expenditures | $0 | -$1.06M |
| Free Cash Flow | -$162.63M | -$20.28M |
| FCF Per Share | -$0.33 | -$0.41 |
Efficiency
| Measure | Gossamer Bio | Industry median |
|---|---|---|
| Asset Turnover | 0.34 | 0.38 |
| Revenue Per Employee | $330.97K | $398.96K |
| Profits Per Employee | -$777.78K | -$732.08K |
| Employee Count | 161 | 73 |
Dividends and yields
| Measure | Gossamer Bio | Industry median |
|---|---|---|
| Earnings Yield | -3.04% | -21.2% |
| FCF Yield | -3.95% | -7.64% |
Shares
| Measure | Gossamer Bio | Industry median |
|---|---|---|
| Shares Outstanding | 488,847,000 | 59,128,900 |
| Shares Change (YoY) | 12.8% | 11.1% |
| Shares Change (QoQ) | 108.3% | 0.54% |
| Float | 475,268,000 | 48,744,500 |
| Shares Held by Insiders | 2.78% | 11.8% |
| Shares Held by Institutions | 78.1% | 59.4% |
Scores
| Measure | Gossamer Bio | Industry median |
|---|---|---|
| Altman Z-Score | -19.73 | 0.10 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Gossamer Bio's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.